Durata Therapeutics Announces Five Abstracts Concerning Dalbavancin and Management of abSSTI at ICAAC 2012
Jed WeinerWhite Oak Communications, Inc.(847) 392-4186orDurata TherapeuticsCorey FishmanChief Operating Officer and Chief Financial Officer(973) 993-4865orLee M. SternThe Trout Group LLC(646) 378-2922
Durata Therapeutics (NASDAQ: DRTX) today announced that data from multiple studies of its investigational drug dalbavancin and of the outpatient management of acute bacterial skin and soft tissue infection (abSSTI) will be presented in five posters during the 52 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference will be held in San Francisco, CA from September 9-12, 2012.
*Note: all times are listed in Pacific Time.
Dalbavancin is an intravenous antibiotic product candidate under investigation for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI, caused by Gram-positive bacteria, such as S. aureus, including Methicillin-Resistant and multi-drug resistant strains, and certain streptococcal species. The product candidate is a semi-synthetic lipoglycopeptide designed and under investigation for once-weekly intravenous dosing which may facilitate the treatment of patients with abSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient’s hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI.
Any statements in this press release about Durata’s future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.